fingolimod hydrochloride has been researched along with Carcinoma, Squamous Cell in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Gębka-Kępińska, B; Sowa, P; Zięba, N | 1 |
| da Silva, G; Garcia, CB; Goto, RN; Leopoldino, AM; Sobral, LM; Stringhetta-Padovani, K; Vitek, MP | 1 |
| Chen, MC; Chiang, SL; Hua, CH; Ko, YC; Lee, CH; Lin, SH; Velmurugan, BK; Yeh, KT | 1 |
| Bai, LY; Chiu, CF; Chiu, SJ; Chu, PC; Weng, JR | 1 |
| Benedetti, MD; Bozzetti, S; Gajofatto, A; Gobbin, F; Marangi, A; Mocella, S; Pea, M; Turatti, M | 1 |
| Corbett, A; Kermode, AG; Reddel, SW; Triplett, J | 1 |
| Herr, DR; Ibrahim, MH; Johnson, SP; Lai, SL; Lopes, V; Murray, PG; Narayanaswamy, P; Panja Bernam, S; Paterson, IC; Patmanathan, SN; Torta, F; Wei, W; Wenk, MR; Yap, LF | 1 |
1 review(s) available for fingolimod hydrochloride and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Skin Neoplasms | 2022 |
6 other study(ies) available for fingolimod hydrochloride and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Proliferation; Cell Survival; DNA-Binding Proteins; Drug Synergism; Fingolimod Hydrochloride; Histone Chaperones; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; NF-kappa B; Peptides; Protein Phosphatase 2; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Female; Fingolimod Hydrochloride; Glycogen Synthase Kinase 3 beta; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Mouth Neoplasms; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Phosphorylation; Proportional Hazards Models; Protein Phosphatase 2; Risk Factors; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Tyrosine | 2018 |
FTY720 Induces Autophagy-Associated Apoptosis in Human Oral Squamous Carcinoma Cells, in Part, through a Reactive Oxygen Species/Mcl-1-Dependent Mechanism.
Topics: Apoptosis; Autophagy; Carcinoma, Squamous Cell; Caspases; Cytoprotection; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Mouth Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured | 2017 |
HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod.
Topics: Carcinoma, Squamous Cell; Fingolimod Hydrochloride; Human papillomavirus 16; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Papillomavirus Infections; Tonsillar Neoplasms | 2018 |
Warts and all: Fingolimod and unusual HPV-associated lesions.
Topics: Ankle; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cryotherapy; Fingers; Fingolimod Hydrochloride; Foot Dermatoses; Hand Dermatoses; Humans; Imiquimod; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis, Relapsing-Remitting; Papillomavirus Infections; Warts | 2019 |
Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2.
Topics: Aldehyde-Lyases; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Cisplatin; Drug Synergism; Female; Fingolimod Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Lysophospholipids; Male; Middle Aged; Mouth Neoplasms; Phenotype; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors | 2016 |